Factory 99% Osimertinib Mesylate Powder CAS 1421373-66-1 Chemical Intermediate Azd-9291

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: A771
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Name: Osimertinib Mesylate
• CAS: 1421373-66-1
• Appearance: White Powder
• Assay: 99%
• OEM: Available
• Sample: Available
• Suitable: Adult
• MOQ: 1g
• Function: Chemical Intermediate
• Transport Package: Foil Bag
• Specification: 99
• Trademark: /
• Origin: China
• Production Capacity: 10000 Kgs Per Month

Product Description

 

Product Name	Osimertinib Mesylate
Appearance	White Powder
CAS NO.	1421373-66-1
Storage	Keep in a cool, dry, dark location

 

Osimertinib Mesylate is a potent EGFR (Epidermal Receptor) inhibitor, specifically classified as a third-generation, covalent, irreversible, and mutation-selective agent. Below is a concise description of its applications and functions:

 

1. Cancer Treatment: Osimertinib Mesylate is primarily used in the treatment of non-small cell lung cancer (NSCLC) that has developed resistance to first- and second-generation EGFR inhibitors, particularly those harboring the T790M mutation.
2. Therapeutic Agent in Clinical Trials: It is also being investigated in clinical trials for other types of cancers, exploring its potential as a broad-spectrum antitumor agent.
3. Combination Therapy: Researchers are exploring the use of Osimertinib Mesylate in combination with other therapies to enhance treatment efficacy and overcome drug resistance.

1. Inhibition of EGFR Mutations: Osimertinib Mesylate binds covalently and irreversibly to the EGFR, particularly the T790M mutation, effectively inhibiting its signaling pathways and tumor growth.
2. Improved Patient Outcomes: By targeting resistant EGFR mutations, Osimertinib Mesylate has demonstrated improved progression-free survival and overall survival in clinical trials, significantly benefiting patients with NSCLC.
3. Minimal Off-Target Effects: Its mutation-selective properties minimize off-target effects, reducing potential adverse reactions and improving treatment tolerability.